The Biomolecules and Biomedicine is an international, peer-reviewed journal. Journal IF 2024: 2.2 Broad readership and scope. Open Access. Editorial Board.
The Biomolecules and Biomedicine (formerly, the Bosnian Journal of Basic Medical Sciences, BJBMS) is а premier venue for preclinical and clinical biomedical science discoveries. The journal was founded in 1998 and is published by the Association of Basic Medical Sciences, a nonprofit honor organization of physician-scientists. The Biomolecules and Biomedicine reaches readers across a wide range of
medical disciplines and sectors. The Journal publishes basic and translational/clinical research submissions and reviews in all biomedical specialties, including Genetics and Molecular biology, Immunology, Microbiology, Pathology, Biochemistry, Pharmacology, Anatomy, Biomaterials, New and Emerging Research and Diagnostic Methods, New and Emerging Medical Entities, and others. All research is available to the public for free. The Biomolecules and Biomedicine deposits published articles in PubMed Central, satisfying the NIH Public Access Policy and other similar funding agency requirements. Renowned international experts in the Journal's Editorial Board, together with external peer-reviewers, select the best submissions for publication. High visibility
Open Access: articles are freely available to readers immediately after publication. Highly accessed online content: more than 350,000 readers/month (100,000 at PubMed Central (April 2024); 120,000 at Journal's website (April 2024); more than 130,000 at Web of Science, Scopus, Google Scholar, and others). Newsletters: more than 20,000 registered users receive a newsletter tailored to their field of interest. Social media: articles are promoted through various social media channels (Twitter, LinkedIn, Facebook)
Advance online: all accepted articles are published Advance online and Ahead of print on PubMed within 3 days of acceptance, with citable DOIs, to make the article accessible as fast as possible. Print circulation: 200 copies of print issues are sent to major libraries, institutes, universities, conferences, and subscribers worldwide. BiomolBiomed Viewpoints: Journal's blog promotes authors and their research by publishing plain language summaries for a broad audience and media, as well as commentaries, interviews, news, and stories related to science and research. Indexing and abstracting
SCIE (Science Citation Index Expanded), Web of Science, Clarivate Analytics
JCR (Journal Citation Reports®), Clarivate Analytics
PubMed/MEDLINE (Biomol Biomed)
PubMed/MEDLINE (BJBMS)
PubMed Central (PMC)
SCOPUS
SJR (Scimago Journal and Country Rank) (BiomolBiomed)
SJR (Scimago Journal and Country Rank) (BJBMS)
DOAJ
SCILIT (BiomolBiomed)
SCILIT (BJBMS)
EBSCO
PROQUEST
Dimensions
Semantic Scholar
Google Scholar
EMBASE/Excerpta Medica
Europe PubMed Central
Medscape
ISSN Portal
ROAD
HINARI
CAS
X-MOL
CNKI
many libraries
Timely publication
The 2023 peer review performance metrics:
Number of submissions (2023): 1288
Average time from submission to initial decision (reject or peer review): 2 days
Average peer-review time and decision: 22 days
Average time from acceptance to advance online publication: 2 days
Average number of reviews received per manuscript: 4
Acceptance Rate: 15%
Meaningful metrics
The success of the articles published in BiomolBiomed is tracked in real-time by individualized Article-Level Metrics (Dimensions and PlumX). These reflect the viewership, download rates, social sharing, citations, field citation ratio, and relative citation ratio for each published article in real-time, and help you illustrate the impact of your research
COPD and Immunotherapy in NSCLC
Can chronic obstructive pulmonary disease improve response to immune checkpoint inhibitors?
A systematic review and meta-analysis of 13 retrospective cohorts (n=5,564) found that NSCLC patients with COPD had longer progression-free and overall survival when treated with ICIs compared to those without COPD. Effects were consistent across subgroups, with the strongest signal in CT-diagnosed emphysema.
Contrary to its traditional role as a negative prognostic factor, COPD may confer an immune contexture that enhances ICI efficacy—possibly via increased PD-L1 expression, elevated tumor mutational burden, and greater CD8+ infiltration.
COPD and Immunotherapy in NSCLC: Meta-analysis of 5,564 patients shows COPD linked to longer PFS/OS with ICIs; CT emphysema shows strongest signal.
08/09/2025
Background and rationale Lung cancer remains the leading cause of cancer-related mortality worldwide; non-small cell lung cancer (NSCLC) accounts for about 85% of cases. Despite advances, prognosis is poor, especially at advanced stages. Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, or CTLA-4 have transformed the therapeutic landscape, but responses vary, underscoring the need for predictive factors. Chronic obstructive pulmonary disease (COPD)—a progressive inflammatory condition with persistent airflow limitation—is common in NSCLC, with reported rates of 40–70%, largely due to shared risk factors such as smoking....
COPD and Immunotherapy in NSCLC: Meta-analysis of 5,564 patients shows COPD linked to longer PFS/OS with ICIs; CT emphysema shows strongest signal.
05/09/2025
Menopause and T-Helper Cells in Women With AMI
Can menopausal status reshape immune balance during acute myocardial infarction?
A proof-of-concept study found sex-specific immune differences—women showed higher CD4+ counts and a Th1 shift compared to men—but menopausal status did not significantly alter T-helper subsets or cytokines. Postmenopausal women carried higher clinical risk scores, raising questions about how hormonal status intersects with cardiovascular risk in AMI.
Menopause and T-Helper Cells in Women With AMI: study shows sex-specific immune shifts, but menopausal status did not alter Th profiles.
03/09/2025
Pollution and Epigenetics: A Hidden Driver of Diabetes
Can environmental pollutants reprogram genes to increase diabetes risk?
Emerging evidence shows that chemicals like particulate matter, arsenic, and BPA may alter gene expression through epigenetic mechanisms—DNA methylation, histone modifications, and microRNA regulation—shaping insulin secretion, glucose metabolism, and beta-cell function.
Activation of the AhR/CYP1 pathway by pollutants triggers oxidative stress, inflammation, and epigenetic reprogramming. For instance, arsenic modifies SQSTM1 methylation, diesel exhaust upregulates miR-375, and TCDD drives histone hyperacetylation at key promoters. These changes disrupt insulin sensitivity and may persist across life stages.
Animal studies confirm that blocking AhR improves insulin response, highlighting this pathway as a central link between environment and diabetes. The findings suggest pollutants are not just bystanders but active drivers of metabolic dysfunction.
Pollution and Epigenetics: A Hidden Driver of Diabetes—exploring how environmental toxins alter gene expression and raise diabetes risk.
01/09/2025
Breakthroughs in Cervical Cancer Immunotherapy and Biomarker Research
Can new immunotherapies, vaccines, and targeted drugs improve cervical cancer survival?
Cervical cancer affects over 660,000 women and causes more than 348,000 deaths each year, mostly in countries with limited access to screening and HPV vaccination. Most cases are caused by persistent infection with high-risk HPV types 16 or 18.
In advanced disease, pembrolizumab (for PD-L1–positive tumors) and cemiplimab have improved survival compared with chemotherapy. When pembrolizumab was added to chemoradiotherapy in locally advanced disease, 3-year survival reached 82.6% versus 74.8%. Cadonilimab (33% response rate) and neoadjuvant camrelizumab + chemotherapy (98% response) show strong activity in early trials.
Therapeutic HPV vaccines, such as PDS0101 + CRT (88% response), VGX-3100, and GX-188E, have shown encouraging results in trials. Antibody–drug conjugates (tisotumab vedotin; trastuzumab deruxtecan, sacituzumab govitecan) have achieved response rates around 50% in some studies. Key biomarkers include PD-L1 (~90%), high tumor mutational burden, MSI-H (rare), HRD (~16%), and circulating tumor HPV DNA for disease monitoring.
Breakthroughs in Cervical Cancer Immunotherapy and Biomarker Research are transforming treatment, offering hope for personalized care.
28/08/2025
𝐴𝑟𝑡𝑒𝑚𝑖𝑠𝑖𝑎 𝑎𝑛𝑛𝑢𝑎 Yields Potent Inhibitor Against Alpha SARS-CoV-2 Variant
Can plant-derived compounds from 𝘈. 𝘢𝘯𝘯𝘶𝘢 block Alpha-variant replication?
𝘐𝘯 𝘷𝘪𝘵𝘳𝘰, an arteannuin B–rich fraction from 𝘈. 𝘢𝘯𝘯𝘶𝘢 showed the strongest activity (EC₅₀ = 38.1 µg/mL) against a high-infectivity Alpha strain (N501Y; Δ69–70; Δ144), outperforming other extracts and pure artemisinin (inactive). At effective doses, it cut viral gene amplification by 84–100% with no significant cytotoxicity.
Extracts were obtained via supercritical CO₂ and ethanol methods, then purified by HSCCC, revealing arteannuin B—not artemisinin—as the key antiviral.
Likely mechanism: covalent inhibition of SARS-CoV-2 Mpro.
Artemisia annua yields potent inhibitor against Alpha SARS-CoV-2 variant, with arteannuin B showing strong antiviral activity in vitro.
25/08/2025
Deep Learning Predicts HER2 Status in Breast Cancer Using Ultrasound and MRI
Can US and MRI deep learning models improve non-invasive HER2 prediction?
In 197 women with invasive breast cancer, DL models trained on ultrasound (ConvNeXt V2) and MRI (3D ResNet18) were tested alone and in combination. DL-US reached an AUC of 0.842 with high sensitivity (89.5%), DL-MRI achieved 0.800, and the combined model hit 0.898 with perfect specificity (100%).
US captured superficial detail and vascularity, while MRI revealed tumor heterogeneity—making the combined approach promising for confirmatory diagnosis when biopsy results are inconclusive. This is the first study to merge US and MRI deep learning for HER2 prediction, paving the way for larger multicenter trials.
Deep Learning Predicts HER2 Status in Breast Cancer Using Ultrasound and MRI, enabling non-invasive, accurate preoperative assessment.
22/08/2025
RNA-Binding Proteins in NAFLD: Roles and Emerging Drug Target
Can targeting RNA-binding proteins (RBPs) improve the diagnosis and treatment of NAFLD and NASH?
A review of experimental studies identifies HuR, PTBP1, hnRNPs, IGF2BP2, and others as key post-transcriptional regulators driving lipid buildup, inflammation, and fibrosis. HuR shows both protective and harmful effects; PTBP1 and IGF2BP2 fuel lipogenesis; hnRNPs influence insulin sensitivity and cholesterol handling.
Mechanistic insights link RBPs to lncRNA and mRNA regulation in NAFLD, with preclinical drugs—like TUDCA, obeticholic acid, flavonoids, and metformin—modulating their activity.
These findings support RBP profiling for NAFLD/NASH risk and urge clinical trials of RBP-targeted therapies.
RNA-Binding Proteins in NAFLD: Roles and Emerging Drug Target insights reveal how RBPs shape lipid metabolism, inflammation, and therapy
20/08/2025
Green-Synthesized Zinc Oxide Nanoparticles Show Broad Antimicrobial Potential
Could desert plant–derived ZnONPs become the next frontier in fighting drug-resistant microbes?
Using four hardy medicinal desert plants — 𝘛𝘩𝘺𝘮𝘦𝘭𝘢𝘦𝘢 𝘩𝘪𝘳𝘴𝘶𝘵𝘢, 𝘈𝘭𝘰𝘦 𝘷𝘦𝘳𝘢, 𝘙𝘦𝘵𝘢𝘮𝘢 𝘮𝘰𝘯𝘰𝘴𝘱𝘦𝘳𝘮𝘢, and 𝘗𝘦𝘨𝘢𝘯𝘶𝘮 𝘩𝘢𝘳𝘮𝘢𝘭𝘢 — researchers produced zinc oxide nanoparticles (ZnONPs) through a green, eco-friendly process. These biosynthesized particles showed unique size, morphology, and phytochemical coatings that enhanced their antimicrobial action.
Across bacterial, yeast, and fungal pathogens, ZnONPs — particularly from 𝘈. 𝘷𝘦𝘳𝘢 and 𝘗. 𝘩𝘢𝘳𝘮𝘢𝘭𝘢 — demonstrated inhibition zones up to 24 mm, often outperforming plant extracts or zinc salts alone. Computational docking linked key phenolic and flavonoid compounds to strong, stable interactions with microbial target proteins such as 𝘚. 𝘢𝘶𝘳𝘦𝘶𝘴 TyrRS and 𝘊. 𝘢𝘭𝘣𝘪𝘤𝘢𝘯𝘴 secreted aspartic proteinase.
Most phytochemicals met drug-likeness criteria, with promising bioavailability and synthetic accessibility, underscoring their pharmaceutical potential.
Green-synthesized zinc oxide nanoparticles show broad antimicrobial potential, providing eco-friendly defense against bacteria, yeasts, and fungi.
20/08/2025
Background: The Growing Need for Alternative Antimicrobial Strategies Nanoparticles (NPs) — materials with sizes between 10 and 100 nanometers — have attracted attention across science and technology for their unique properties. In medicine, they are being explored for drug delivery, antimicrobial and antioxidant applications, and diagnostics. Traditional chemical and physical methods for NP production are often costly, time-consuming, and environmentally hazardous....
Green-synthesized zinc oxide nanoparticles show broad antimicrobial potential, providing eco-friendly defense against bacteria, yeasts, and fungi.
18/08/2025
Inflammation Alters Pain-Sensing Nerves in Guinea Pigs, Not Rats
Could species-specific nerve changes improve pain research models?
Chronic inflammatory pain changes how nerves detect and send pain signals—but not in the same way for all species. Using the complete Freund’s adjuvant model, researchers found that guinea pig nociceptors became faster and more excitable after inflammation, with higher conduction velocities, shorter action potentials, and briefer recovery times. These changes can enhance pain signal transmission.
Rats, however, showed no significant nerve changes, suggesting species-specific differences in ion channel function. Given their closer similarity to some aspects of human sensory biology, guinea pigs may offer a more accurate model for certain types of inflammatory pain.
Inflammation Alters Pain-Sensing Nerves in Guinea Pigs, Not Rats, revealing species-specific changes in nociceptors linked to chronic pain
15/08/2025
August 2025 Issue is now online!
The latest issue of Biomolecules and Biomedicine (Vol. 25, Issue 8) is now live—and it’s packed with insights into emerging molecular mechanisms and therapeutic targets in cancer research.
Inside this issue:
- Reviews on tumor hypoxia and exosome-based drug delivery
- Meta-analyses evaluating treatment safety and outcomes
- Original research on key pathways like HIF-1α, Wnt/β-catenin, Fascin 1, and ST6GAL1
From cell lines to animal models, these studies illuminate the evolving landscape of cancer biology and offer fresh perspectives for translational medicine.
The Biomolecules and Biomedicine is a premier open-access biomedical journal covering a wide range of preclinical, translational and clinical research.
Be the first to know and let us send you an email when Biomolecules and Biomedicine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
The BJBMS (Bosnian Journal of Basic Medical Sciences) is а premier venue for discoveries in basic and clinical biomedical science. The BJBMS was founded in 1998 and is published by the Association of Basic Medical Sciences, a nonprofit honor organization of physician-scientists.
Broad readership and scope. The BJBMS reaches readers across a wide range of medical disciplines and sectors. The journal publishes basic and translational/clinical research submissions and reviews in all biomedical specialties, including Genetics and Molecular biology, Immunology, Microbiology, Pathology, Biochemistry, Pharmacology, Anatomy, Biomaterials, new and emerging research and diagnostic methods, new and emerging medical entities, and others.
Open access. All research is available to the public for free. The BJBMS deposits published articles in PubMed Central, which satisfies the NIH Public Access Policy and other similar funding agency requirements.
Editorial Board. Renowned international experts in the journal's Editorial Board, together with external peer-reviewers select the best of the submissions for publication.
High visibility
Open Access: articles are freely available to readers immediately after publication.
Highly accessed online content: more than 150,000 visits/month (45,000 at PubMed Central (October 2019); 50,000 at Journal's website (March 2020); 45,000 at Web of Science, Scopus, Google Scholar, and others).
Newsletters: more than 9,000 registered users receive a newsletter tailored to their field of interest.
Social media: articles are promoted through various social media channels (Twitter, LinkedIn, Facebook)
Advanced online: all accepted articles are published Advanced online and Ahead of print on PubMed within 3 days of acceptance, with citable DOIs, to make the article accessible as fast as possible.
Print circulation: 300 copies of print issues are sent to major libraries, institutes, universities, conferences, and subscribers across the globe. Get the free sample copy here.
BJBMS Viewpoints: Journal's blog that promotes authors and their research by publishing plain language summaries for wide audience and media, as well as commentaries, interviews, news and stories related to science and research.
Indexing and abstracting
Science Citation Index Expanded (Web of Science, Clarivate Analytics)
Journal Citation Reports® (JCR)
PubMed/MEDLINE
PubMed Central (PMC)
SCOPUS
DOAJ
EBSCO
PROQUEST
Dimensions
Semantic Scholar
Google Scholar
EMBASE/Excerpta Medica
Europe PubMed Central
Medscape
ROAD
HINARI
CAS
many libraries
Timely publication
Time to First Editorial Decision (Rejection or Peer Review): 3 days
Time to First Decision after review (Rejection or Revision or Acceptance): 25 days
Time from Acceptance to Publication: 3 days (if no significant language editing is required)
Rejections without peer review: 40%
Acceptance Rate: 15%
Meaningful metrics
The success of the articles published in BJBMS is tracked in real-time by individualized Article-Level Metrics (Dimensions and PlumX). These reflect the viewership, download rates, social sharing, citations, field citation ratio, and relative citation ratio for each published article in a real-time, and help you illustrate the impact of your research
